This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here.

Turbidimetric Solubility Assay

Understand if poor solubility is likely to be an issue in the development of your compound.

Turbidimetric solubility is one of Cyprotex's in vitro ADME screening services. Cyprotex deliver consistent, high quality data with cost-efficiency that comes from a highly automated approach.

The role of turbidimetric solubility measurement in early discovery

  • Poor solubility can limit the quality of the data generated in other in vitro assays. Therefore, it is essential to evaluate solubility at an early stage in drug discovery.
  • The solubility of a compound is an important factor in determining its absorption from the gastrointestinal tract and ultimately its oral bioavailability.
  • Compounds with poor solubility can pose a development challenge and result in prolonged development time frames and increased cost.
  • Turbidimetric solubility is now an accepted early stage screen in drug discovery. Cyprotex's Turbidimetric Solubility assay investigates the kinetic solubility of compounds by diluting a test compound solution prepared in DMSO into aqueous buffer. Turbidimetry is used as the end-point by measuring absorbance at 620 nm.
  • Turbidimetric solubility allows a rapid determination of solubility using small amounts of compound.
While thermodynamic solubility is useful when preparing a data package for a proposed development candidate, kinetic solubility seems most appropriate for high throughput in vitro assays in discovery.

1Kerns EH and Di L. (2005) Journal of the Association for Laboratory Automation 10(2); 114-123


Turbidimetric solubility assay protocol

Final Test Article Concentration 1 μM, 3 μM, 10 μM, 30 μM and 100 μM
Buffer 0.01 M phosphate buffered saline pH7.4
(alternatives available on request)
Final DMSO Concentration 1%
Number of Replicates n = 7 per concentration
Incubation Time 2 hours
Incubation Temperature 37°C
Test Article Requirements 150 μL of a 10 mM solution
Analysis Method Absorbance at 620 nm
Data Delivery Estimated solubility range (lower and upper bound and calculated mid-range in μM).

Prediction of Human Intestinal Absorption
Cyprotex's Turbidimetric Solubility data can be used in conjuction with Caco-2 Permeability data to predict dose dependent human intestinal absorption.  Please refer to our Cloe Predict Human Intestinal Absorption Model section for further details.


Data from Cyprotex's Turbidimetric Solubility assay

Data generated in Cyprotex's assay compare well with third party data.

CompoundCyprotex's Turbidimetric Solubility (μg/ml)Blind Trial Solubility by
LC-UV/MS (μg/ml)
1 0.5 <1
2 0.7 <1
3 0.8 <1
4 1.6 <1
5 5.6 2.2
6 26.5 89
7 30.8 43.9
8 31.8 9.3
9 >19.2 81
10 >26.2 48.8
11 >30.8 158.9
12 >33.3 113.6
13 >33.8 176.7
14 >41.2 200.3
15 >41.4 >41.4
16 >42.7 119.6
17 >44.2 222
18 >44.3 177.8
19 >45 237.7
20 >45.1 203.1
21 >46.4 >46.4
22 >47.1 166.4
23 >50 260
24 >52.1 279
Table 1
Comparison of Cyprotex's Turbidimetric Solubility with third party solubility data.

In a blind trial, Cyprotex's solubility results for discovery compounds compared well to a customer’s own solubility data. All compounds ranked in close agreement with regards to their solubility profiles.
Figure 1
Mean solubility data generation by Cyprotex's Turbidimetric Solubility assay at pH7.4 (error bars represent the standard deviation of 4 replicates).
Figure 2
Comparison of Cyprotex's Turbidimetric Solubility results with third party data generated by HPLC-UV/VIS.


Questions and answers on turbidimetric solubility

Please provide an overview of Cyprotex's Turbidimetric Solubility assay.

Aqueous solubility is measured using a high throughput turbidimetric assay. Initially, a stock DMSO solution is diluted in DMSO to produce a range of concentrations. These are then added to buffer, typically phosphate buffered saline at pH 7.4 (final test compound concentrations = 1 µM, 3 µM, 10 µM, 30 µM, 100 µM, final DMSO concentration = 1%, 7 replicates per concentration) and incubated for 2hr at 37°C. At the end of the incubation period, the absorbance at 620nm is read for each concentration and each replicate.

Figure 3
Typical Solubility Profile showing the Effect of Increasing the Test Compound Concentration on Absorbance (at 620 nm) for the Control Compound Pyrene.

Estimated precipitation range = 3 – 10 µM

A program has been developed in-house to calculate the estimated solubility, with the onset of precipitation based on an increase in absorbance. As the calculation is to some extent based on inflection point, the maximum can vary from the set of concentrations tested. The solubility can also cover a wide range if the program does not feel it can accurately calculate the value.

Why is solubility important?

Poor solubility can limit the absorption of compounds from the gastrointestinal tract which reduces oral bioavailability. The quality of the data generated from the in vitro assays can also be affected by poor solubility.

How do I interpret the data from the solubility assay?

A precise measure of solubility can not be provided using the turbidimetric assay. The data are reported as an estimated precipitate range (i.e. lower bound, upper bound and calculated mid-range). It can be assumed that at some point within this range the compound precipitates. For ranking purposes clients typically use lower bound value. For drug discovery compounds, most clients would consider a compound which has a solubility value of less 1 µM to be highly insoluble, between 1 and 100 µM to be partially soluble and > 100 µM to be soluble. Although poor solubility is obviously an undesirable situation, it does not necessary preclude the development of an otherwise promising compound. If the compound has very high permeability, and is highly potent in vivo, then solubility may become less limiting. Formulation can also be used to improve the solubility.

The data can be used for a variety of purposes. Firstly, it can provide useful information for chemists to assess the effect of functional groups on the solubility of a series of compounds. The data can also be used to direct formulation strategy. Secondly, the solubility data can be useful for interpreting the results from the in vitro assays. If a compound has a solubility value lower than the test compound concentration in the in vitro screen then the results achieved for that screen may be inaccurate. Thirdly, solubility can be used in conjunction with other in vitro parameters to predict the oral pharmacokinetics of a compound using the simulation software, Cloe PK.

Inaccurate solubility readings may be caused by compounds which are insoluble in the original DMSO solution, or if the compound is a blue or green color, which causes interference at the wavelength of 620 nm. In drug discovery, most colored compounds tend to be red or yellow, rather than blue or green. Therefore, the problem of interference is relatively rare.

Can the solubility assay be performed at different pH values?

Yes we are able to perform the assay at different pH values. Often clients will request pH 2 and pH 6 to mimic the conditions present in the stomach and small intestine respectively. For ionizable compounds, aqueous solubility is dependent on pH. If a compound has no ionizable groups then its solubility will be unaffected by the pH of the buffer.

What control compounds are used in the turbidimetric solubility screen?

Pyrene and nicardipine are used as the positive control compounds. The solubility of pyrene is pH-independent whereas nicardipine displays pH-dependent solubility.


1 Kerns EH and Di L. (2005) Journal of the Association for Laboratory Automation 10(2); 114-123

Cloe® is a registered trademark owned by Cyprotex PLC

Request a Quote
Speak to a Scientist
Product sheet ADME-Tox Guides Pricing & Discounts

Contact us to discuss your ADME Tox issues or request a quote

North America (East Coast): 888-297-7683
Europe: +44 1625 505100


or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.